Pre-made Lampalizumab benchmark antibody ( Fab, anti-CFD therapeutic antibody, Anti-ADIPSIN/ADN/DF/PFD Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lampalizumab biosimilar, Fab, Anti-CFD Antibody: Anti-ADIPSIN/ADN/DF/PFD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Lampalizumab (INN) is an antigen-binding fragment of a humanized monoclonal antibody that binds to complement factor D; it was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-293-1mg	1mg	3090
GMP-Bios-ab-293-10mg	10mg	Inquiry
GMP-Bios-ab-293-100mg	100mg	Inquiry
GMP-Bios-ab-293-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lampalizumab biosimilar, Fab, Anti-CFD Antibody: Anti-ADIPSIN/ADN/DF/PFD therapeutic antibody
INN Name	Lampalizumab
Target	CFD
Format	Fab
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	4d9q:HL:ED/4d9r:HL:ED
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2012
Year Recommended	2013
Companies	Tanox;Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Dry age-related macular degeneration
Development Tech	na